Endpoints takes its China biotech debate to DC: four Post-Hoc Live conversations on patents, FDA data, biosecurity and ...
All 50 states, DC and Puerto Rico join CMS' Generous model, tying Medicaid drug prices to what other wealthy countries pay.
China's new five-year plan targets 20% annual pharma revenue growth and a quarter of the world's first-in-class drugs by 2030 ...
Legend Biotech has tapped Novartis executive Ingrid Zhang as its new CEO at a time when the company is seeking its next act.
The FDA approved a new combination regimen from Eli Lilly for certain breast cancer patients, a regimen that includes Lilly’s oral selective estrogen receptor degrader (SERD) ...
An FDA report pushes back on claims it's rejecting more drugs, showing first-cycle rejection rates fell from 47% in 2008 to about 27% in 2024.
Anthropic launched a Life Sciences Verification Program, granting select researchers access to AI models Mythos, Opus, and Sonnet, while maintaining biosafety restrictions on high-risk biological ...
Therapeutics prices its Nasdaq IPO, 2026's 21st biotech float, to fund a Phase 2/3 trial of immunology drug ipsoprubart.
CMS signaled drugmakers joining its Generous Medicaid rebate demo would be exempt from the Globe and Guard Medicare pilots, ...
FDA grants accelerated approval to Ultragenyx's Sanfilippo gene therapy UX111, weeks after the biotech's Angelman Phase 3 ...
CART01; Ori bags $120M deal; Reckitt invests $600M in US; Astellas expands Ireland; Hovione opens NJ facility.
Six UK parliamentary committees ask the National Audit Office to probe the cost of the £1B UK-US pharma deal and its NHS ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results